Senseonics (NYSE:SENS) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Senseonics (NYSE:SENS) in a report issued on Saturday. The firm issued a sell rating on the stock.

Separately, HC Wainwright reiterated a buy rating and issued a $2.00 target price on shares of Senseonics in a research report on Wednesday, August 14th.

Senseonics Price Performance

Shares of NYSE:SENS opened at $0.35 on Friday. The company’s fifty day moving average is $0.40 and its two-hundred day moving average is $0.44. The company has a market cap of $184.70 million, a P/E ratio of -2.49 and a beta of 0.79. Senseonics has a 12-month low of $0.32 and a 12-month high of $0.75. The company has a quick ratio of 2.89, a current ratio of 3.11 and a debt-to-equity ratio of 59.17.

Senseonics (NYSE:SENS) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.03). Senseonics had a negative return on equity of 299.69% and a negative net margin of 335.15%. The firm had revenue of $4.87 million during the quarter, compared to the consensus estimate of $4.86 million. Equities analysts expect that Senseonics will post -0.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Senseonics

Several institutional investors have recently made changes to their positions in SENS. RPO LLC bought a new position in Senseonics during the fourth quarter valued at about $37,000. State Board of Administration of Florida Retirement System acquired a new stake in Senseonics in the 1st quarter worth approximately $91,000. Virtu Financial LLC bought a new stake in Senseonics during the first quarter worth approximately $162,000. Cubist Systematic Strategies LLC boosted its position in Senseonics by 25.9% during the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after purchasing an additional 85,501 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Senseonics by 16.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock valued at $196,000 after purchasing an additional 51,000 shares during the period. 12.36% of the stock is currently owned by institutional investors and hedge funds.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.